Referred to the House Committee on Energy and Commerce.
The bill states that the Department of Health and Human Services final rule titled “Medications for the Treatment of Opioid Use Disorder” (89 Fed. Reg. 7549; published February 2, 2024) shall have no force or effect, except for the portion of that final rule that modifies subpart B of part 8 of title 42, Code of Federal Regulations (the provisions relating to accreditation of opioid treatment programs), which the bill leaves in place.
Whether the HHS rule expanded evidence-based access to medication for opioid use disorder (progressives see repeal as reducing access; conservatives view repeal as reining in federal overreach).
Relative to its intended legislative type, this bill narrowly and explicitly nullifies a single HHS final rule (with a specified exception) and does so with clear referencing and a simple statutory mechanism.
The bill states that the Department of Health and Human Services final rule titled “Medications for the Treatment of Opioid Use Disorder” (89 Fed.
Reg. 7549; published February 2, 2024) shall have no force or effect, except for the portion of that final rule that modifies subpart B of part 8 of title 42, Code of Federal Regulations (the provisions relating to accreditation of opioid treatment programs), which the bill leaves in place.
On content alone the bill is narrow and administratively straightforward, which helps its prospects in the originating chamber; however, it addresses a politically salient health regulation and lacks compromise mechanisms beyond a small carve-out. Without broad bipartisan support or clear, widespread stakeholder backing, such a regulatory rollback is unlikely to clear both chambers and be enacted, so the overall likelihood is low-to-moderate.
Relative to its intended legislative type, this bill narrowly and explicitly nullifies a single HHS final rule (with a specified exception) and does so with clear referencing and a simple statutory mechanism. It provides minimal implementation scaffolding beyond that nullification.
Whether the HHS rule expanded evidence-based access to medication for opioid use disorder (progressives see repeal as reducing access; conservatives view repeal as reining in federal overreach).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether the HHS rule expanded evidence-based access to medication for opioid use disorder (progressives see repeal as reducing access; conservatives view repeal as reining in federal overreach).
A mainstream liberal would likely view this bill as a rollback of an HHS rule on treatment for opioid use disorder and therefore problematic because it removes enacted federal regulatory changes that were intended to affect care for people with opioid use disorder.
They would be concerned that nullifying the rule (other than accreditation changes) could reduce access to evidence-based medications and create confusion for providers and patients.
They would emphasize the public-health risks of removing measures that may have expanded or eased access to medications for opioid use disorder.
A centrist/moderate would weigh the bill as a mixed intervention: it asserts legislative authority over a significant HHS regulatory change while preserving accreditation provisions.
They would want clarity about which operational elements are being repealed and worry about unintended disruption to patient care and provider operations.
They are likely to seek compromise solutions—fix specific problematic rule provisions through a more targeted legislative or administrative approach rather than a blunt nullification.
A mainstream conservative would generally welcome congressional nullification of an HHS final rule they perceive as federal regulatory overreach, especially if the rule loosened constraints on MOUD prescribing or clinic operations.
They would view the bill as restoring legislative authority and leaving in place accreditation standards that maintain program oversight.
Some conservatives may still want assurances that patient safety and continuity of care are preserved, but overall the bill aligns with priorities to limit expansive executive-branch regulation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is narrow and administratively straightforward, which helps its prospects in the originating chamber; however, it addresses a politically salient health regulation and lacks compromise mechanisms beyond a small carve-out. Without broad bipartisan support or clear, widespread stakeholder backing, such a regulatory rollback is unlikely to clear both chambers and be enacted, so the overall likelihood is low-to-moderate.
The bill has not accumulated any surfaced votes yet.
Whether the HHS rule expanded evidence-based access to medication for opioid use disorder (progressives see repeal as reducing access; cons…
On content alone the bill is narrow and administratively straightforward, which helps its prospects in the originating chamber; however, it…
Relative to its intended legislative type, this bill narrowly and explicitly nullifies a single HHS final rule (with a specified exception) and does so with clear referencing and a simple statutory mechanism. It provide…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.